Novartis arbeider for å skape økt verdi for pasienter og våre samarbeidspartnere innen helsevesenet. Vi vil påvirke menneskers liv i en positiv retning gjennom å oppdage, utvikle og markedsføre nye produkter for å helbrede sykdommer og forbedre menneskers livskvalitet.
Nedenfor finner du et utvalg av studier som er gode og viktige innen temaene:
- Migrene (prevalens og sykdomsbyrde)
- CGRP
- Erenumab (Aimovig)
Studier om migrene
One-year prevalence of migraine in Sweden: a population-based study in adults
Dahlöf C1, Linde M; Cephalalgia. 2001 Jul;21(6):664-71.
The global burden of headache Saylor D, Steiner T.J, Semin Neurol. 2018
Apr;38(2):182-190. Epub 2018 May 23.
Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015
GBD 2015 Disease and Injury Incidence and Prevalence Collaborators, Lancet. 2016 Oct 8;388(10053):1545-1602.
Studier om CGRP
CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatmen
Edvinsson L, Br J Clin Pharmacol. 2015 Aug; 80(2): 193-199.
The Journey to Establish CGRP as a Migraine Target: A Retrospective Vie
Edvinsson L, Headache. 2015 Oct;55(9):1249-55. doi: 10.1111/head.12656. Epub 2015 Sep 14.
Calcitonin Gene-Related Peptide (CGRP) and Migraine
Durham P.L, Headache. 2006 Jun; 46(Suppl 1): S3-S8.
CGRP as the target of new migraine therapies — successful translation from bench to clinic
Edvinsson L, Haanes K.A, Warfvinge K, Krause D.N. Nature Reviews Neurologyvolume 14, pages 338-350 (2018).
CGRP: Sensory neuropeptide with multiple neurologic implications
Benarroch E.E, Neurology. July 19, 2011; 77 (3).
Calcitonin Gene-Related Peptide (CGRP) and Migraine
Russo AF, Annu Rev Pharmacol Toxicol. 2015;55:533-52. doi: 10.1146/ annurevpharmtox- 010814-124701. Epub 2014 Oct 8.
Studier om erenumab
Long-term safety and efficacy of erenumab in patients with chronic migraine: results from a 52-week open-label study https://engraffo.com/p/RFnOlovDaD
Tepper S J et al. Cephalalgia 2020 vol 40(6) 543-553
Long-term efficacy and safety of erenumab in migraine prevention: results from a 5-year, open-label treatment phase of a randomized clinical trial https://docintel.app/WileyUK/mmPAvdnn
Ashina M et al. European journal of neurology, Nov 2020. DOI: 10.1111/ene.14715
Two-year efficacy and safety of erenumab in participants with episodic migraine and 2-4 prior preventive treatment failures: results from the LIBERTY study
Ferrari MD, et al. Two-year efficacy and safety of erenumab in participants with episodic migraine and 2-4 prior preventive treatment failures: results from the LIBERTY study.J Neurol Neurosurg Psychiatry. 2022;93(3):254-262.
Erenumab versus topiramate for the prevention of migraine - a randomised, double-blind, active-controlled phase 4 trial
Reuter U, et al. Erenumab versus topiramate for the prevention of migraine - a randomised, double-blind, active-controlled phase 4 trial.Cephalalgia. 2022;42(2):108-118.
Safety & Tolerability evaluation of Erenumab for the preventive treatment of migraine Expert Opinion on Drug Safety
Deligianni C I et al, Informa, Expert Opinion on Drug Safety, Aug 2021 DOI: 10.1080/14740338.3031.1933 841
Erenumab decreases headache-related sick leave days and health care visits: A retrospective realworld study in working patients with migraine
Autio H, Nissilä M. et al. Neurol Ther, Dec 2021 https://doi.org/10.1007/s40120-021-00303-x
Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised. double-blind, placebocontrolled phase 2 trial
Tepper S et al, The Lancet, Jun 2017, issue 6, P425-434.
A Controlled Trial of Erenumab for Episodic Migraine
Goadsby P.J, Reuter U, Hallström Y, Broessner G, Bonner J.H, Zhang F, SapraS, Picard H, Mikol D.D, Lenz R.A, N Engl J Med 2017;377:2123-2132.
NO2401128620